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This editorial refers to ‘DREADD technology reveals major
impact of Gq signaling on cardiac electrophysiology’ by
E. Kaiser et al., pp. 1052–1066.
G protein-coupled receptors (GPCRs) are the most common receptors
on the surface of cardiomyocytes. GPCRs coupled to Gq play a central
role in mediating the response of cardiac tissue to several hormones.
Angiotensin-II (acting on the AT1 receptor), endothelin-1 (ETA recep-
tor), and noradrenaline/adrenaline (alpha-adrenergic receptor) are the
main hormones that share the intracellular signalling associated with Gq
protein in the cardiomyocyte.
Activation of Gq-coupled receptors in the heart leads to proarrhythmic
consequences (see Figure 1). AT1 receptors contribute to the pathogene-
sis of supraventricular and ventricular arrhythmias, and chronic AT1 block-
ade in cardiac patients is protective against the development of atrial
fibrillation and sustained ventricular arrhythmias.1,2 Activation of a1 recep-
tors may contribute to adrenergic-induced arrhythmias on top of the
more relevant b1 and b2 receptor stimulation.
3 Indeed, pharmacological
inhibition of a-receptors combined with b-block provides an additional
antiarrhythmic protection in patients with arrhythmic syndromes such as
catecholaminergic polymorphic ventricular tachycardia (CPVT).4
Moreover, phenylephrine, a selective a1-receptor agonist, causes acute
atrial fibrillation in animal models.5 Activation of ETA receptors by
endothelin-1 may be involved in the generation of ventricular arrhythmias
in the presence of acute myocardial ischaemia.6
Based on pioneer studies in cardiac tissue and cells, several effec-
tors have been proposed as mediators of the proarrhythmic activity
of Gq-coupled receptors, such as Naþ/Hþ antiport for the a1-recep-
tors.7 However, whether arrhythmias are mediated by changes in the
cardiomyocyte function or in the activity of other myocardial cells
(fibroblasts and smooth muscle) remains unclear. Similarly, the benefi-
cial effects of a number of drugs commonly employed in cardiovascu-
lar therapy to treat hypertension, such as AT1 receptor blockers
(losartan and others sartans), ETA blockers (bosentan and others,
used for pulmonary hypertension), and a1A blockers (tamsulosin and
others) have been poorly explored in terms of their direct antiar-
rhythmic potential.
Kaiser et al.8 first obtained a selective hyperactivation of the Gq path-
way in the working and conduction cardiomyocytes employing a de-
signer receptors solely activated by designer drugs (DREADD)
technology. In brief, by using a combined genetic/chemical approach, an
exogenous ‘designer receptor’ associated to a Gq-like protein (Dq pro-
tein) is introduced in the cardiomyocyte sarcolemma (and expressed
both on the surface and the t-tubules). The receptor has no constitutive
activity and is stimulated by the acute administration of an exogenous ag-
onist [clozapine-N-oxide (CNO)] that exerts its effects within a few
minutes. The authors show that the activation of the Gq pathway leads
to ventricular and supraventricular tachyarrhythmias and degree 1 and 2
AV block, with no changes in the action potential profile. The arrhythmic
events can be ascribed to a reduction in conduction velocity and the
authors suggest that the effect could be mediated by the interplay be-
tween spatially co-localized Dq and connexin CX43.
Compared to previous work exploring the Gq signalling with pharma-
cological agonists/antagonists of Gq-coupled receptors,1,5,6 a major ad-
vantage of this technique resides in its spatio-temporal precision. The
work by Kaiser et al.8 represents the first evidence of ‘cardiomyocyte-
specific’ effects of the Gq-coupled receptors, although no functional
discrimination between cardiomyocyte sub-types was envisaged (e.g.
working vs. conduction myocardium, atrial vs. ventricular, or endocardial
vs. epicardial myocytes).
Important insight on cardiac arrhythmias can be obtained by extending
the possibility of controlling the G protein signalling in vivo within a spe-
cific cell type. On this respect, cell type-specific DREADD expression
could by easily achieved using viral or transgenic approaches. For exam-
ple, this can allow controlling the G protein cascade at sinoatrial or AV
node as well as in the cardiac conduction system (e.g. Purkinje fibre) dis-
tinctly from the working myocardium. DREADD expressions through
systemic delivery of viral vectors could allow challenging the hyperactiva-
tion of specific pathways also in animal models that mimic acquired or
genetic cardiac diseases.
For sake of comparison, Beiert et al.9 recently showed that a light-
sensitive Gq-coupled receptor (melanopsin) is a powerful optogenetic
tool for the investigation of spatial and temporal aspects of Gq signalling
in the heart. On this respect, patterned illumination10 could be very
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..useful in performing confined receptor activation across single cells or
specific tissue regions. This could overcome limitations of standard deliv-
ery of pharmacological agonists where global diffusion prevent sharp
localizations. However, as light needs to be very close to the target tissue
or organ, optogenetic studies in vivo often need to be performed in
open-chest approaches, with enormous limitations for the application in
awake and freely moving animals, with no possibilities to study the effects
of the chronic Gq pathway activation.
To date, in addition to Gq DREADDs, other signalling cascades have
been selectively interrogated in neuroscience studies by means of CNO-
activated DREADDs (Gi, Gs, and b-arrestin),11 and could be of interest
for the cardiovascular field. For instance, DREADD-mediated activation
of Gi signalling could help elucidating whether the alternative response
or diverse sublocalization of b2-adrenergic receptors are involved in the
pathogenesis of Takotsubo cardiomyopathy,12,13 and whether it involves
a localized enhancement of Gi signalling in apical cardiomyocytes due to
high levels of circulating epinephrine. The modulatory proteins b-arrest-
ins contribute to desensitization of many GPCR (e.g. b-adrenergic and
AT1) and initiate alternate signalling pathways, often involving nuclear
expression regulation.14 Selective cardiomyocyte-specific activation of
b-arrestin may be useful to clarify the extent by which the effects of
GPCRs depend on G protein independent pathways and to demonstrate
whether a selective modulation of b-arrestin pathway may serve as a
therapeutic strategy in cardiac diseases.15 DREADD-mediated activation
of b-arrestin and Gs in cardiomyocytes may help defining which of the
downstream effects of b-receptors are dependent on each of the two al-
ternative pathways.
In the era of emerging chemogenetics where DREADDs appear as an
extremely promising technology to study selective intracellular signalling
in the cardiomyocytes, a few limitations could be envisaged. Among
them, the difficulty to obtain a compartmentalized response (e.g. recep-
tors located in the surface sarcolemma vs. t-tubules) or to reproduce
Figure 1 Gq signalling and arrhythmias. Figure depicting the proposed mechanisms underlying the induction of arrhythmias upon activation of Gq-linked
GPCRs. Activation of ETA, a1, or AT1 receptors on the cardiomyocyte surface leads to activation of Gq proteins that in turn activate phospholipase-C
(PLC). PLC hydrolyses phosphatidylinositol triphosphate (PI3) to inositol triphosphate (IP3)þ diacylglycerol (DAG). IP3 activates IP3 receptors on the sarco-
plasmic reticulum, which lead to enhanced release of Ca2þ from the SR, while DAG activates protein-kinase C (PKC), which in turn phosphorylates several
targets including L-type Ca-channels (DHPR), which ultimately contribute to intracellular Ca-overload. Moreover, sustained increase of diastolic [Ca2þ]
leads to activation of Ca-calmodulin kinase II (CAMK) that further aggravates Ca-overload and facilitates spontaneous diastolic openings of the Ryanodine
receptor (RYR2). The increased rate of spontaneous diastolic Ca release and Ca-waves cause delayed after depolarizations (DADs, i.e. spontaneous depola-
rizations occurring during the diastolic period), caused by diastolic activation of electrogenic Na–Ca-exchange. DADs may cause premature action poten-
tials and may initiate arrhythmias. Moreover, either through a direct action of Gq or via PKC-mediated phosphorylation, Cx43 connexin assemblies are
made dysfunctional, thus reducing myocardial conduction speed and increasing the risk of re-entry.
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..some pleiotropic responses of the naı¨ve receptors. To date, this technol-
ogy cannot re-create all the downstream effects of GPCRs, in particular
those that are not dependent on G-proteins. Notably, several long-term
effects of AT-1 receptor activation (cardiac hypertrophy and rhythm dis-
turbances) are independent on Gq signalling and may rely on alternate
pathways.
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